Literature DB >> 33572108

Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression.

Roosa Kaarijärvi1, Heidi Kaljunen1, Kirsi Ketola1.   

Abstract

Neuroendocrine plasticity and treatment-induced neuroendocrine phenotypes have recently been proposed as important resistance mechanisms underlying prostate cancer progression. Treatment-induced neuroendocrine prostate cancer (t-NEPC) is highly aggressive subtype of castration-resistant prostate cancer which develops for one fifth of patients under prolonged androgen deprivation. In recent years, understanding of molecular features and phenotypic changes in neuroendocrine plasticity has been grown. However, there are still fundamental questions to be answered in this emerging research field, for example, why and how do the prostate cancer treatment-resistant cells acquire neuron-like phenotype. The advantages of the phenotypic change and the role of tumor microenvironment in controlling cellular plasticity and in the emergence of treatment-resistant aggressive forms of prostate cancer is mostly unknown. Here, we discuss the molecular and functional links between neurodevelopmental processes and treatment-induced neuroendocrine plasticity in prostate cancer progression and treatment resistance. We provide an overview of the emergence of neurite-like cells in neuroendocrine prostate cancer cells and whether the reported t-NEPC pathways and proteins relate to neurodevelopmental processes like neurogenesis and axonogenesis during the development of treatment resistance. We also discuss emerging novel therapeutic targets modulating neuroendocrine plasticity.

Entities:  

Keywords:  axonogenesis; cancer cell plasticity; neurobiology of cancer; neuroendocrine differentiation; neuroendocrine plasticity; neurogenesis; novel therapies; prostate cancer; treatment-induced neuroendocrine prostate cancer

Year:  2021        PMID: 33572108      PMCID: PMC7915380          DOI: 10.3390/cancers13040692

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  174 in total

1.  Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells.

Authors:  Kirsi Ketola; Paula Vainio; Vidal Fey; Olli Kallioniemi; Kristiina Iljin
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

2.  ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells.

Authors:  Nicole I Park; Paul Guilhamon; Kinjal Desai; Rochelle F McAdam; Ellen Langille; Madlen O'Connor; Xiaoyang Lan; Heather Whetstone; Fiona J Coutinho; Robert J Vanner; Erick Ling; Panagiotis Prinos; Lilian Lee; Hayden Selvadurai; Gurnit Atwal; Michelle Kushida; Ian D Clarke; Veronique Voisin; Michael D Cusimano; Mark Bernstein; Sunit Das; Gary Bader; Cheryl H Arrowsmith; Stephane Angers; Xi Huang; Mathieu Lupien; Peter B Dirks
Journal:  Cell Stem Cell       Date:  2017-07-14       Impact factor: 24.633

Review 3.  Androgens in the etiology of Alzheimer's disease in aging men and possible therapeutic interventions.

Authors:  Stephanie J Fuller; Robert S Tan; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

Review 4.  Considering the evolution of regeneration in the central nervous system.

Authors:  Elly M Tanaka; Patrizia Ferretti
Journal:  Nat Rev Neurosci       Date:  2009-10       Impact factor: 34.870

5.  REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons.

Authors:  J A Chong; J Tapia-Ramírez; S Kim; J J Toledo-Aral; Y Zheng; M C Boutros; Y M Altshuller; M A Frohman; S D Kraner; G Mandel
Journal:  Cell       Date:  1995-03-24       Impact factor: 41.582

6.  Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.

Authors:  Mohammed Alshalalfa; Paul L Nguyen; Himisha Beltran; William S Chen; Elai Davicioni; Shuang G Zhao; Timothy R Rebbeck; Edward M Schaeffer; Tamara L Lotan; Felix Y Feng; Brandon A Mahal
Journal:  Eur Urol Oncol       Date:  2019-06-02

Review 7.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Authors:  Alastair H Davies; Himisha Beltran; Amina Zoubeidi
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

8.  BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2.

Authors:  Divya Bhagirath; Thao Ly Yang; Z Laura Tabatabai; Shahana Majid; Rajvir Dahiya; Yuichiro Tanaka; Sharanjot Saini
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

Review 9.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

10.  Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.

Authors:  Irene Gutiérrez-Cañas; María G Juarranz; Beatriz Collado; Nieves Rodríguez-Henche; Antonio Chiloeches; Juan C Prieto; María J Carmena
Journal:  Prostate       Date:  2005-04-01       Impact factor: 4.104

View more
  4 in total

Review 1.  Killing SCLC: insights into how to target a shapeshifting tumor.

Authors:  Kate D Sutherland; Abbie S Ireland; Trudy G Oliver
Journal:  Genes Dev       Date:  2022-03-01       Impact factor: 11.361

Review 2.  Role of MicroRNAs in Neuroendocrine Prostate Cancer.

Authors:  Amritha Sreekumar; Sharanjot Saini
Journal:  Noncoding RNA       Date:  2022-03-30

Review 3.  The Role of Perineural Invasion in Prostate Cancer and Its Prognostic Significance.

Authors:  Yuequn Niu; Sarah Förster; Michael Muders
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

4.  Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.

Authors:  Jiping Yao; Yanning Liu; Xue Liang; Jiajia Shao; Yina Zhang; Jing Yang; Min Zheng
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-08       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.